Slower growth in new electronic medical record contracts due to clinical testing price negotiations and profitability management
First written in FY2017. 4 of 6 entries say "Restated". Latest entry: FY2022-Q3.
0 other companies' latest entry also says "Restated".
- FY2022-Q3RestatedAnnual report
「During the cumulative third quarter of the fiscal year, there were no material changes in the financial position, operating results, or cash flow situation, including any abnormal fluctuations, or in the business and other risks described in the annual securities report for the previous fiscal year. There were also no material events or other matters of concern.」
It states that there were no material changes to the previously disclosed risk of slower growth in new electronic medical record contracts resulting from clinical testing price negotiations and profitability management. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter of the fiscal year, there were no material changes in the financial position, operating results, or cash flow situation, including any abnormal fluctuations, or in the business and other risks described in the annual securities report for the previous fiscal year. There were also no material events or other matters of concern.」
It states that there were no material changes to the previously disclosed slowdown in new electronic medical record contract growth resulting from clinical testing price negotiations and profitability management. - FY2019MitigatedAnnual report
「In the medical information systems business, replacements of the clinic version of the electronic medical records systems, Qualis and Medical Station (MS), proceeded smoothly, while maintenance revenue remained steady as the number of installed systems increased. As a result, revenue increased 6.1% from the previous fiscal year.」
Regarding the slowdown in new electronic medical record contract growth associated with the focus on clinical testing price negotiations and profitability management, it states that the medical information systems business increased revenue during the period and that replacement demand was also solid. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter of the fiscal year, there were no material changes in the financial position, operating results, or cash flow situation, including any abnormal fluctuations, or in the business and other risks described in the annual securities report for the previous fiscal year. There were also no material events or other matters of concern.」
It states that there were no material changes to the previously disclosed slowdown in new electronic medical record contract growth resulting from clinical testing price negotiations and profitability management. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no material changes in the financial position, operating results or cash flow, including any abnormal fluctuations, or in the “Business and Other Risks” described in the annual securities report for the previous fiscal year. There are also no material events or similar matters.」
It states that there were no material changes to the previously disclosed slowdown in new electronic medical record contract growth resulting from clinical testing price negotiations and profitability management. - FY2017MaterialisedAnnual report
「Revenue declined 1.7% year on year, mainly because growth in the number of new contracts acquired slowed as the clinical testing business focused on price negotiations following revisions to reimbursement rates and on profitability management.」
It states that growth in the number of new contracts in the medical information systems business actually slowed as the clinical testing business focused on price negotiations and profitability management.